Hematologic Cancer Clinical Trial
— POMFITTOfficial title:
Laser Photobiomodulation to Prevent Oral Mucositis and Functional Impairment Among Adult Hematologic Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to test the efficacy of laser photobiomodulation in adult hematologic cancer patients undergoing hematopoietic stem cell transplantation (HSCT). The main questions it aims to answer are: • Is photobiomodulation with laser in the oral cavity, compared to standard care, effective in preventing oral mucositis and functional impairments in adult patients receiving HSCT? • What is the level of patient´s acceptability of photobiomodulation with laser in the oral cavity during HSCT? Participants once a day will receive photobiomodulation (diode laser device) in their oral cavity from the first day of transplantation conditioning until third day post-transplant. Researchers will compare with usual care to see if photobiomodulation helps preventing oral mucositis and functional impairment.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | October 30, 2025 |
Est. primary completion date | October 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Adults over 18 years of age with hematological neoplasms who require medical indication of an HSCT according to the Transplant Committee at Clinica Dávila - With sufficient understanding of Spanish. Exclusion Criteria: - Observed cognitive deficit - Patients who do not meet the criteria of clinical stability, progression of the disease, and that do not fulfill requirement of the National Hematopoietic Stem Cell Transplantation Program. - Participants with an oral infection from any type of Candida prior to HSCT. |
Country | Name | City | State |
---|---|---|---|
Chile | Clinica Dávila | Santiago | Metropolitana |
Lead Sponsor | Collaborator |
---|---|
Universidad del Desarrollo | Agencia Nacional de Investigación y Desarrollo, Clínica Dávila |
Chile,
Bohannon RW, Crouch RH. Two-Minute Step Test of Exercise Capacity: Systematic Review of Procedures, Performance, and Clinimetric Properties. J Geriatr Phys Ther. 2019 Apr/Jun;42(2):105-112. doi: 10.1519/JPT.0000000000000164. — View Citation
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-4431. doi: 10.1002/cncr.33100. Epub 2020 Jul 28. Erratum In: Cancer. 2021 Oct 1;127(19):3700. — View Citation
Ferreira B, da Motta Silveira FM, de Orange FA. Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. Support Care Cancer. 2016 Mar;24(3):1035-42. doi: 10.1007/s00520-015-2881-8. Epub 2015 Aug 7. — View Citation
Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999 Jun;70(2):113-9. doi: 10.1080/02701367.1999.10608028. — View Citation
McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A, Hurd DD. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant. 1997 Feb;19(4):357-68. doi: 10.1038/sj.bmt.1700672. — View Citation
Rikli RE, Jones CJ. Development and validation of criterion-referenced clinically relevant fitness standards for maintaining physical independence in later years. Gerontologist. 2013 Apr;53(2):255-67. doi: 10.1093/geront/gns071. Epub 2012 May 20. — View Citation
Robijns J, Nair RG, Lodewijckx J, Arany P, Barasch A, Bjordal JM, Bossi P, Chilles A, Corby PM, Epstein JB, Elad S, Fekrazad R, Fregnani ER, Genot MT, Ibarra AMC, Hamblin MR, Heiskanen V, Hu K, Klastersky J, Lalla R, Latifian S, Maiya A, Mebis J, Migliorati CA, Milstein DMJ, Murphy B, Raber-Durlacher JE, Roseboom HJ, Sonis S, Treister N, Zadik Y, Bensadoun RJ. Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022. Front Oncol. 2022 Aug 30;12:927685. doi: 10.3389/fonc.2022.927685. eCollection 2022. — View Citation
Tribolet P, Kaegi-Braun N, Gressies C, Baumgartner A, Wagner KH, Stanga Z, Schuetz P. Handgrip Strength Values Depend on Tumor Entity and Predict 180-Day Mortality in Malnourished Cancer Patients. Nutrients. 2022 May 23;14(10):2173. doi: 10.3390/nu14102173. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oral Mucositis | It refers to the maximal degree of oral mucositis developed after stem cell transplantation. It will be recorded daily from the first day after stem cell transplantation up to the day 20 after transplantation). The World Health Organization (WHO) oral mucositis scale will be used. Scores range from 0 (no mucositis), 1 (pain/erythema), 2 (erythema, ulcers; can eat solid foods), 3 (ulceration, requiring only a liquid diet), to 4 (oral feeding is not possible). The higher the grade, the worse the mucositis. | From the first day up to the 20th after stem cell transplantation (or up to the day of hospital discharge if prior to day 20) | |
Primary | Level of Pain | It refers to the perceived level of pain related to oral mucositis from a numeric scale (0 to 10), where 0 means "no pain" and 10 "the worse possible pain". Higher scores means more pain. | From the first day up to the 20th day after stem cell transplantation (or up to the day of hospital discharge if prior to day 20) | |
Secondary | Handgrip strength | It is the maximal isometric strength of the handgrip that will be measured in KgF with Hydraulic Hand Dynamometer (Jamar Digital Plus®). | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Exercise tolerance | The exercise capacity of an individual as measured by endurance (maximal exercise duration and/or maximal attained work load) during an EXERCISE TEST. It will be assessed with the 2-Minute Walking Test is a functional test that assesses an individual's aerobic capacity and is used as a performance measure. | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Physical fitness | It is the ability to carry out daily tasks and perform physical activities in a highly functional state, often as a result of physical conditioning. Physical fitness will be evaluated with the 30-Second Sit and Stand (SST30') assesses the ability to rise from a chair and sit back down, as well as the strength and functionality of the lower limbs. | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Health related quality of life | Health related quality of life is a generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. Quality of life will be assessed using the validated and widely used instrument in the oncology population undergoing hematopoietic stem cell transplantation, the Functional Assessment of Cancer Therapy-Bone Marrow Transplant questionnaire. | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Length of hospital stay | Number of hospitalization days/bed days from the day of admission to medical discharge | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Use of opioids | The number of days that the patient required analgesic medication (opioids) and receives it to alleviate oral mucositis pain from the onset of oral mucositis according to World Health Organization criteria until medical discharge. | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Body mass index | The body mass index is a person's weight in kilograms divided by the square of height in meters. It will be obtained from the patient's clinical file. Higher values mean malnutrition due to body weight excess and lower values mean malnutrition due to underweight. It will be classified according to World Health Organization: underweight (<18.5), normal weight (18,5 to 24.9), overweight (25 to 29.9) and obesity (>30). | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Nutritional status | Nutritional status has been defined as an individual's health condition as it is influenced by the intake and utilization of nutrients. The evaluation of the nutritional status will be through the Subjective Global Evaluation. This scale classifies patients in: well nourished, mildly/moderately malnourished, or severely malnourished. | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Daily calorie intake | It correspond to the mean of daily calorie intake (kcal/day) of the patient. It will be obtained from the hospital record. Higher values mean higher calorie intake. | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Arm circumference | It is the circumference of the arm (cm) that will be measured in the mean point between the distance of olecranon and acromion with relaxed arm and elbow flexed at 90 degrees. | Through study completion on the day of hospital discharge, an average of 1 month | |
Secondary | Triceps skinfold | Corresponds to the thickness of the triceps region (mm). It will be assessed with a skinfold caliper. Higher values indicate more body fat. | Through study completion on the day of hospital discharge, an average of 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04966156 -
Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT
|
N/A | |
Recruiting |
NCT05942885 -
Hypnosis: a Path to Appeasement
|
N/A | |
Recruiting |
NCT05715047 -
Intervention for Fatigue in HCT Recipients
|
N/A | |
Recruiting |
NCT05142033 -
Avera Cancer Sequencing and Analytics Protocol (ASAP)
|
||
Completed |
NCT06053918 -
Research-Action in Hematology From Hospitalization to Home
|
||
Recruiting |
NCT05175508 -
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04822974 -
TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS
|
N/A | |
Not yet recruiting |
NCT06279585 -
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
|
N/A | |
Recruiting |
NCT05753501 -
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT05481502 -
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
|
N/A | |
Not yet recruiting |
NCT04412135 -
The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
|
||
Not yet recruiting |
NCT06377059 -
Early Detection of Complications During Immunotherapy for Haematological Malignancy
|
N/A | |
Completed |
NCT04235153 -
CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
|
||
Recruiting |
NCT05626764 -
QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
|
||
Active, not recruiting |
NCT04035447 -
Symptom Management for YA Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT05602168 -
Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance
|
N/A | |
Terminated |
NCT03955276 -
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
|
||
Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01792882 -
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
|
||
Active, not recruiting |
NCT05493800 -
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
|
Phase 2 |